| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
155,920 |
118,331 |
$6.68M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
46,952 |
38,780 |
$2.93M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
35,299 |
28,632 |
$2.18M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
2,683 |
2,103 |
$332K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,810 |
2,387 |
$224K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,736 |
3,552 |
$137K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
709 |
680 |
$74K |
| 64483 |
|
387 |
218 |
$28K |
| 99215 |
Prolong outpt/office vis |
446 |
392 |
$21K |
| 96127 |
|
4,687 |
3,564 |
$17K |
| 62323 |
|
238 |
199 |
$16K |
| 27096 |
|
160 |
108 |
$7K |
| 99406 |
|
601 |
565 |
$3K |
| 77002 |
|
92 |
79 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
768 |
610 |
$2K |
| 99490 |
Ccm add 20min |
144 |
122 |
$1K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
1,868 |
1,780 |
$1K |
| 20610 |
|
27 |
25 |
$937.90 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
149 |
129 |
$733.86 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
29 |
25 |
$530.60 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
698 |
451 |
$253.67 |
| 99439 |
|
38 |
29 |
$216.44 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,461 |
1,104 |
$214.61 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
14 |
13 |
$34.16 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
12,551 |
11,961 |
$0.22 |
| 1036F |
|
320 |
298 |
$0.12 |
| 1101F |
|
2,225 |
2,117 |
$0.05 |
| G8734 |
Elder maltreatment screen documented as negative, follow-up is not required |
193 |
185 |
$0.03 |
| 1006F |
|
1,796 |
1,700 |
$0.02 |
| 1124F |
|
681 |
647 |
$0.02 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
22 |
21 |
$0.01 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
2,505 |
2,395 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,229 |
2,126 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,154 |
1,105 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
6,275 |
5,995 |
$0.00 |
| 1123F |
|
805 |
769 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
496 |
478 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
273 |
261 |
$0.00 |
| G8542 |
Functional outcome assessment using a standardized tool is documented; no functional deficiencies identified, care plan not required |
891 |
847 |
$0.00 |
| G8433 |
Screening for depression not completed, documented patient or medical reason |
41 |
40 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
8,063 |
7,677 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,426 |
1,349 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
1,100 |
1,040 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
4,576 |
4,357 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
18,447 |
17,507 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
1,265 |
1,205 |
$0.00 |
| G8942 |
Functional outcome assessment using a standardized tool is documented within the previous 30 days and a care plan, based on identified deficiencies is documented within two days of the functional outcome assessment |
22 |
20 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
121 |
116 |
$0.00 |
| G8938 |
Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible |
62 |
61 |
$0.00 |
| 4004F |
|
143 |
130 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
33 |
33 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
191 |
184 |
$0.00 |
| 1100F |
|
12 |
12 |
$0.00 |
| 3288F |
|
12 |
12 |
$0.00 |